Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
Open Access
- 26 November 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Objectives: To present the long-term (4-year) efficacy and safety of secukinumab in Taiwanese patients with active AS in the MEASURE 1 extension study. Methods: This post hoc analysis reports data from Taiwanese patients originally randomized to subcutaneous secukinumab 150 or 75mg or placebo every 4 weeks (following intravenous loading dose) who were invited to enter the 3-year extension study. Assessments at Week 208 included ASAS20/40 responses and other clinically relevant endpoints. Efficacy data are presented as observed. Safety analyses included all patients who received ≥1 dose of secukinumab. Results: Of the 57 Taiwanese patients in the core trial, 48 entered the extension study and 87.5% patients (42/48) completed 4 years of treatment. Thirteen Taiwanese patients (including placebo-switchers) were escalated from 75 to 150mg (approved dose) at some point starting from Week 172. ASAS20/40 responses were sustained through 4 years in the Taiwanese patients who were originally randomized to secukinumab 150mg. Clinical responses were improved in those patients who received dose-escalation from 75 to 150mg during the study. No unexpected safety signals were reported. Conclusion: Secukinumab 150mg demonstrated sustained efficacy over 4 years in Taiwanese patients with active ankylosing spondylitis. The safety profile of secukinumab was consistent with previous reports. ClinicalTrials.gov identifier: NCT01863732.This publication has 21 references indexed in Scilit:
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisThe New England Journal of Medicine, 2015
- American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisArthritis & Rheumatology, 2015
- Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease‐Modifying Antirheumatic DrugsArthritis & Rheumatology, 2015
- Adverse effects of TNF inhibitors in SpA: Are they different from RA?Best Practice & Research Clinical Rheumatology, 2014
- Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitisInternational Immunopharmacology, 2014
- Risk of tuberculosis with anti‐tumor necrosis factor‐α therapy: substantially higher number of patients at risk in AsiaInternational Journal of Rheumatic Diseases, 2013
- Ankylosing Spondylitis: Chinese Perspective, Clinical Phenotypes, and Associated Extra-articular Systemic FeaturesCurrent Rheumatology Reports, 2013
- Similarities and differences between spondyloarthritis in Asia and other parts of the worldCurrent Opinion in Rheumatology, 2011
- Hepatitis B virus reactivation during therapy with etanercept in an HBsAg‐negative and anti‐HBs‐positive patientLiver International, 2008
- Ankylosing spondylitisThe Lancet, 2007